WB result of Invivo anti-mouse IL-23 (p19) Recombinant Rabbit mAb
Primary antibody: Invivo anti-mouse IL-23 (p19) Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: IL-23 Protein, Mouse 1 µg
Lane 2: IL-23 Protein, Human 1 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 21 kDa
Observed MW: 17 kDa
Product Details
Product Details
Product Specification
Host | Rat |
Antigen | IL-23 (p19) |
Synonyms | Interleukin-23 subunit alpha; IL-23 subunit alpha; IL-23-A; Interleukin-23 subunit p19 (IL-23p19); SGRF; IL23A |
Location | Secreted |
Accession | Q9NPF7、P29460 |
Clone Number | S-2754 |
Antibody Type | Rat mAb |
Isotype | Rat IgG1,k |
Application | WB, Neutralization |
Reactivity | Ms |
Purification | Protein G |
Concentration | 5 mg/ml |
Purity | >95% by SDS-PAGE |
Endotoxin | <2EU/mg |
Conjugation | Unconjugated |
Physical Appearance | Liquid |
Storage Buffer | PBS pH7.4, containing no preservative |
Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Dilution
application | dilution | species |
WB | 1:1000 | Ms |
Background
Interleukin-23 (IL-23) is a heterodimeric cytokine composed of a p19 subunit and a p40 subunit. The p19 subunit is unique to IL-23, while the p40 subunit is shared with IL-12. IL-23 plays a crucial role in the immune system, particularly in the regulation of T cell responses. It is involved in the differentiation and maintenance of Th17 cells, a subset of T helper cells that produce pro-inflammatory cytokines such as IL-17 and IL-22. These Th17 cells are essential for host defense against extracellular pathogens but can also contribute to chronic inflammation and autoimmune diseases when dysregulated. IL-23 signaling occurs through the IL-23 receptor complex, which includes IL-23R and IL-12Rβ1 subunits, and activates downstream pathways like JAK-STAT, leading to the production of various inflammatory mediators. Due to its involvement in immune-mediated inflammatory diseases, IL-23 has become a target for therapeutic interventions, with several biologics targeting the p19 subunit or the IL-23 receptor being developed and used in the treatment of conditions such as psoriasis, Crohn’s disease, and other autoimmune disorders.
Picture
Picture
Western Blot
